Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

The registered record

Accession number

NCT07487948

Lead sponsor

Icahn School of Medicine at Mount Sinai (other)

Collaborators

LEO Pharma

Registered conditions naming hair loss

Central Centrifugal Cicatricial AlopeciaLichen Planopilaris

Official title

A Pilot Study to Assess Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Interventions

• DrugDelgocitinib

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Phase 2

Allocation

non randomized

Masking

none

Primary purpose

treatment

Enrolment

30 participants (estimated)

Sites

1 location in United States

What it measures

1. Changes in IFNγ in CA scalp in delgocitinib-treated patients

   Time frame: Baseline to Week 36

2. Changes in CCL5 in CA scalp in delgocitinib-treated patients

   Time frame: Baseline to Week 36

3. Changes CXCL9 markers in CA scalp in delgocitinib-treated patients

   Time frame: Baseline to Week 36

4. Changes in CXCL10 in CA scalp in delgocitinib-treated patients

   Time frame: Baseline to Week 36

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

all

Age

18 Years

Healthy volunteers

not accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

19 May 2026 (actual)

Primary completion

5 April 2027 (estimated)

Study completion

31 December 2027 (estimated)

First posted

23 March 2026 (actual)

Last update posted

10 July 2026 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: this record registers a primary completion to the day, so a day is what is shown. Where a sponsor registers only a month, only a month is shown.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Scarring Alopecia Types and Management: Complete GuideFrontal Fibrosing Alopecia: Complete Guide to Symptoms, Causes & Treatment (2026)

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT07487948 on ClinicalTrials.gov · All 157 trials in the pipeline